## Mariana Brandao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3186796/publications.pdf

Version: 2024-02-01

932766 839053 20 341 10 18 citations h-index g-index papers 20 20 20 637 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. JCO Global Oncology, 2022, 8, e2100153.	0.8	6
2	Risk Factors for Breast Cancer, Overall and by Tumor Subtype, among Women from Mozambique, Sub-Saharan Africa. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1250-1259.	1.1	4
3	Comparing the cost of non-metastatic breast cancer care in a low-income vs a high-income country: A plea for an optimal allocation of health resources in Sub-Saharan Africa. Breast, 2021, 57, 1-4.	0.9	3
4	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	7.7	79
5	Current and future research efforts in oligometastatic non-small cell lung cancer—a systematic review. Translational Lung Cancer Research, 2021, 10, 3473-3485.	1.3	3
6	Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa. Oncologist, 2021, 26, e996-e1008.	1.9	18
7	Breast cancer subtypes: implications for the treatment and survival of patients in Africa—a prospective cohort study from Mozambique. ESMO Open, 2020, 5, e000829.	2.0	15
8	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open, 2020, 5, e000947.	2.0	63
9	Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype. ESMO Open, 2020, 5, e000984.	2.0	14
10	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open, 2020, 5, e000842.	2.0	16
11	Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. Clinical Breast Cancer, 2020, 20, 262-273.e7.	1.1	14
12	Treatment and Other Healthcare Use of Breast Cancer Patients With a Previous Cancer Diagnosis. Anticancer Research, 2020, 40, 1041-1048.	0.5	2
13	Abstract P6-11-03: Characteristics and survival outcomes of HIV-positive breast cancer patients: A systematic review and meta-analysis. , 2020, , .		1
14	Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an â€~option' but an ethical obligation. ESMO Open, 2019, 4, e000515.	2.0	12
15	Cancer incidence in Mozambique in 2015–2016: data from the Maputo Central Hospital Cancer Registry. European Journal of Cancer Prevention, 2019, 28, 373-376.	0.6	21
16	Long-term follow-up after EMR of large colorectal lesions: metachronous lesions, predictors and surveillance timing. Scandinavian Journal of Gastroenterology, 2019, 54, 1487-1493.	0.6	1
17	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Annals of Oncology, 2019, 30, x27-x42.	0.6	63
18	Factors associated with time to breast cancer diagnosis and treatment in unscreened women in Portugal. Women and Health, 2019, 59, 601-614.	0.4	5

#	Article	IF	CITATIONS
19	Incidental diagnosis of breast cancer in the pursuit of the treatment of intestinal obstruction. Autopsy and Case Reports, 2019, 9, e2018071.	0.2	O
20	Marjolin's Ulcer with Axillary Lymph Node Metastasis. Acta Medica Portuguesa, 2018, 31, 515.	0.2	1